Tie2-Dependent Neovascularization of the Ischemic Hindlimb Is Mediated by Angiopoietin-2

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Lekas, Michael ^a   Lekas, Poli ^a   Mei, Shirley H J ^a,d   Deng, Yupu ^a   Dumont, Daniel J ^b,c   Stewart, Duncan J ^a,b,d  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Sunnybrook Health Sciences Centre   (Canada)

^d OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; PLASMID DNA; VASCULOTROPIN A;

ANGIOGENESIS; ANGIOGENIC GENE THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; GENE OVEREXPRESSION; GENE TRANSFER; LEG ISCHEMIA; LEG REVASCULARIZATION; LIMB BLOOD FLOW; MALE; NONHUMAN; PERFUSION RECOVERY; PLASMID; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; TISSUE PERFUSION;

ANGIOPOIETIN-1; ANGIOPOIETIN-2; ANIMALS; CYTOMEGALOVIRUS; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION; GENETIC THERAPY; GENETIC VECTORS; HINDLIMB; HUMANS; INJECTIONS, INTRAMUSCULAR; ISCHEMIA; MALE; MICE; MICE, KNOCKOUT; NEOVASCULARIZATION, PHYSIOLOGIC; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, TIE-2; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

ANIMALIA; MUS;

EID: 84866688637     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043568     Document Type: Article

References (40)

1. Dumont DJ, Yamaguchi TP, Conlon RA, Rossant J, Breitman ML, (1992) tek, a novel tyrosine kinase gene located on mouse chromosome 4, is expressed in endothelial cells and their presumptive precursors. Oncogene 7: 1471-1480.
2. Sato TN, Tozawa Y, Deutsch U, Wolburg-Buchholz K, Fujiwara Y, et al. (1995) Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 376: 70-74.
3. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, et al. (1996) Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87: 1171-1180.
4. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, et al. (1996) Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380: 435-439.
5. Thurston G, Suri C, Smith K, McClain J, Sato TN, et al. (1999) Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 286: 2511-2514.
6. Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L, et al. (2000) Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 6: 460-463.
7. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, et al. (2000) Vascular-specific growth factors and blood vessel formation. Nature 407: 242-248.
8. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, et al. (1997) Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277: 55-60.
9. Tanaka S, Mori M, Sakamoto Y, Makuuchi M, Sugimachi K, et al. (1999) Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. J Clin Invest 103: 341-345.
10. Peters KG, (1998) Vascular endothelial growth factor and the angiopoietins: working together to build a better blood vessel. Circ Res 83: 342-343.
11. Lobov IB, Brooks PC, Lang RA, (2002) Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci U S A 99: 11205-11210.
12. Goede V, Schmidt T, Kimmina S, Kozian D, Augustin HG, (1998) Analysis of blood vessel maturation processes during cyclic ovarian angiogenesis. Lab Invest 78: 1385-1394.
13. Kim I, Kim JH, Moon SO, Kwak HJ, Kim NG, et al. (2000) Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Oncogene 19: 4549-4552.
14. Teichert-Kuliszewska K, Maisonpierre PC, Jones N, Campbell AI, Master Z, et al. (2001) Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2. Cardiovasc Res 49: 659-670.
15. Asahara T, Chen D, Takahashi T, Fujikawa K, Kearney M, et al. (1998) Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res 83: 233-240.
16. Shyu KG, Manor O, Magner M, Yancopoulos GD, Isner JM, (1998) Direct intramuscular injection of plasmid DNA encoding angiopoietin-1 but not angiopoietin-2 augments revascularization in the rabbit ischemic hindlimb. Circulation 98: 2081-2087.
17. Reiss Y, Droste J, Heil M, Tribulova S, Schmidt MH, et al. (2007) Angiopoietin-2 impairs revascularization after limb ischemia. Circ Res 101: 88-96.
18. Hackett SF, Ozaki H, Strauss RW, Wahlin K, Suri C, et al. (2000) Angiopoietin 2 expression in the retina: upregulation during physiologic and pathologic neovascularization. J Cell Physiol 184: 275-284.
19. Gale NW, Thurston G, Hackett SF, Renard R, Wang Q, et al. (2002) Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell 3: 411-423.
20. Tressel SL, Kim H, Ni CW, Chang K, Velasquez-Castano JC, et al. (2008) Angiopoietin-2 stimulates blood flow recovery after femoral artery occlusion by inducing inflammation and arteriogenesis. Arterioscler Thromb Vasc Biol 28: 1989-1995.
21. Stabile E, Burnett MS, Watkins C, Kinnaird T, Bachis A, et al. (2003) Impaired arteriogenic response to acute hindlimb ischemia in CD4-knockout mice. Circulation 108: 205-210.
22. Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, et al. (1997) Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg 26: 517-538.
23. Arsic N, Zentilin L, Zacchigna S, Santoro D, Stanta G, et al. (2003) Induction of functional neovascularization by combined VEGF and angiopoietin-1 gene transfer using AAV vectors. Mol Ther 7: 450-459.
24. Visconti RP, Richardson CD, Sato TN, (2002) Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF). Proc Natl Acad Sci U S A 99: 8219-8224.
25. Yamauchi A, Ito Y, Morikawa M, Kobune M, Huang J, et al. (2003) Pre-administration of angiopoietin-1 followed by VEGF induces functional and mature vascular formation in a rabbit ischemic model. J Gene Med 5: 994-1004.
26. Fiedler U, Augustin HG, (2006) Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol 27: 552-558.
27. Fiedler U, Reiss Y, Scharpfenecker M, Grunow V, Koidl S, et al. (2006) Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med 12: 235-239.
28. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, et al. (1990) Direct gene transfer into mouse muscle in vivo. Science 247: 1465-1468.
29. Tripathy SK, Svensson EC, Black HB, Goldwasser E, Margalith M, et al. (1996) Long-term expression of erythropoietin in the systemic circulation of mice after intramuscular injection of a plasmid DNA vector. Proc Natl Acad Sci U S A 93: 10876-10880.
30. Comerota AJ, Throm RC, Miller KA, Henry T, Chronos N, et al. (2002) Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial. J Vasc Surg 35: 930-936.
31. Coxon A, Bready J, Min H, Kaufman S, Leal J, et al. (2010) Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody. Mol Cancer Ther 9: 2641-2651.
32. Ahmed A, Fujisawa T, Niu XL, Ahmad S, Al-Ani B, et al. (2009) Angiopoietin-2 confers Atheroprotection in apoE-/- mice by inhibiting LDL oxidation via nitric oxide. Circ Res 104: 1333-1336.
33. Murohara T, Asahara T, Silver M, Bauters C, Masuda H, et al. (1998) Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest 101: 2567-2578.
34. Papapetropoulos A, Garcia-Cardena G, Madri JA, Sessa WC, (1997) Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 100: 3131-3139.
35. Rabbany SY, Heissig B, Hattori K, Rafii S, (2003) Molecular pathways regulating mobilization of marrow-derived stem cells for tissue revascularization. Trends Mol Med 9: 109-117.
36. Bazzoni G, Dejana E, (2004) Endothelial cell-to-cell junctions: molecular organization and role in vascular homeostasis. Physiol Rev 84: 869-901.
37. Schaper W, Scholz D, (2003) Factors regulating arteriogenesis. Arterioscler Thromb Vasc Biol 23: 1143-1151.
38. Zhao YD, Courtman DW, Deng Y, Kugathasan L, Zhang Q, et al. (2005) Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease. Circ Res 96: 442-450.
39. Dumont DJ, Gradwohl G, Fong GH, Puri MC, Gertsenstein M, et al. (1994) Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev 8: 1897-1909.
40. Haninec AL, Voskas D, Needles A, Brown AS, Foster FS, et al. (2006) Transgenic expression of Angiopoietin 1 in the liver leads to changes in lymphatic and blood vessel architecture. Biochem Biophys Res Commun 345: 1299-1307.